Visualize HL7 Example and Test Instances (vi7eti)

Visualize HL7 Example and Test Instances (vi7eti), pronounced /viːˈsɛtiː/

Disclaimer: FOR TEST AND EXAMPLE PURPOSES ONLY! These web pages are not intended to be used as a source of information on medicines. The web pages are not kept up to date and are for demonstration purposes only. For up-to-date information on a medicine, please consult www.ema.europa.eu/medicines or the package leaflet of your medicine.

BACK TO LIST

Patient
Name:	Andresen, , Helene,
DOB:	17-OCT-1939 (Age: 86)
Gender:	female
ID:	3450-170343-2 (ECI)

Author
Dr. Ping, Hel

Patient summary Document
European Patient Summary
Report Date:	30-NOV-2024

Problem list

Condition	Onset Date	Status
Osteoporosis	21-Oct-2018	active
Chronic sinusitis	31-May-1999	active
Hyperlipidemia	07-May-1989	active
Anemia	06-Jul-1963	active
Prediabetes	02-Jul-1960	active
Seizure disorder	19-Apr-1953	active

Medication list

Medication	Since	Form	Dosage	Reason
Simvastatin 10 mg oral tablet	2024-11-30	-	1 tablet (10 mg) by mouth once daily	Hyperlipidemia
Alendronic acid (as alendronate sodium) 10 mg oral tablet	2024-11-23	-	1 tablet (10 mg) once daily	Osteoporosis (disorder)

Immunizations list

Vaccine	Date
Influenza virus antigen only vaccine product	23-Nov-2024
SARS-CoV-2 mRNA vaccine	05-Jun-2021
Clostridium tetani toxoid antigen adsorbed only vaccine product	26-Oct-2019

Procedure History list

Procedure	Date	Reason
Suture open wound	30-Jun-2023	Laceration of hand
Pre-discharge assessment	09-May-2021	-
Discharge from skilled nursing facility (procedure)	09-May-2021	-
Nursing care/supplementary surveillance	08-May-2021	-
Physical therapy procedure	06-May-2021	-
Radiography of humerus	01-May-2021	-
History AND physical examination	01-May-2021	-
Bone immobilization	01-May-2021	Fracture of forearm
Initial patient assessment	01-May-2021	-
Development of individualized plan of care	01-May-2021	-
Occupational therapy	05-Mar-2020	-
Care regimes assessment	04-Mar-2020	-
Professional / ancillary services care	26-Feb-2020	-
Radiography of wrist	16-Feb-2020	-

Allergies and Intolerances

Allergy/Intolerance	Onset Date	Status	Type	Reaction
Inadequate digital access affecting health care	2025-10-22	active	environment

Care Plan

Active Planned Care / Goals	Start Date	Reason
Hyperlipidemia clinical management plan	28-May-1989	Hyperlipidemia
Achieve LDL cholesterol less than 2.6 mmol/L Achieve total cholesterol less than 5.2 mmol/L Maintain HDL cholesterol greater than 1.3 mmol/L Achieve triglycerides less than 1.7 mmol/L
Diabetes self management plan	02-Jul-1960	Prediabetes
Patient will implement and maintain a diabetes self-management plan to reduce risk of progression from prediabetes. Patient will achieve and maintain a healthy weight as part of diabetes self-management. Patient will engage in at least 150 minutes of moderate-intensity physical activity per week.
Immunization Recommendation	Due Date	Reason
Vaccine product containing only Influenza virus antigen (medicinal product)	01-Oct-2025	Annual seasonal influenza vaccination

Vital Signs

Vital Signs	2024-11-23	2023-11-18
Body Height	166.9 cm	166.9 cm
Pain severity - 0-10 verbal numeric rating [Score] - Reported	4 {score}	0 {score}
Body Weight	76.6 kg	76.6 kg
Body mass index (BMI) [Ratio]	27.5 kg/m2	27.5 kg/m2
Diastolic Blood Pressure	83 mm[Hg]	75 mm[Hg]
Systolic Blood Pressure	124 mm[Hg]	127 mm[Hg]
Heart rate	92 /min	81 /min
Respiratory rate	13 /min	15 /min

Relevant diagnostic tests/laboratory data

Recent Lab Observations	30-NOV-2024	Reference Range	Unit
Glucose [Mass/volume] in Blood	86.2	70 - 140	mg/dL
Urea nitrogen [Mass/volume] in Blood	15.0	7 - 25	mg/dL
Creatinine [Mass/volume] in Blood	2.7 H	0.6 - 1.1	mg/dL
Calcium [Mass/volume] in Blood	8.6	8.6 - 10.4	mg/dL
Sodium [Moles/volume] in Blood	142.2	135 - 145	mmol/L
Potassium [Moles/volume] in Blood	5.0	3.5 - 5.3	mmol/L
Chloride [Moles/volume] in Blood	106.8	98 - 108	mmol/L
Carbon dioxide, total [Moles/volume] in Blood	20.6 L	22 - 32	mmol/L
Protein [Mass/volume] in Serum or Plasma	6.7	6.6 - 8.3	g/dL
Albumin [Mass/volume] in Serum or Plasma	4.0	3.5 - 5.5	g/dL
Globulin [Mass/volume] in Serum by calculation	2.2	2.2 - 3.7	g/L
Bilirubin.total [Mass/volume] in Serum or Plasma	0.3	0.3 - 1.2	mg/dL
Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma	44.6	40 - 130	U/L
Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma	43.4	7 - 55	U/L
Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma	15.6	10 - 40	U/L
Cholesterol [Mass/volume] in Serum or Plasma	204.8 H	125 - 200	mg/dL
Triglyceride [Mass/volume] in Serum or Plasma	151.8	10 - 175	mg/dL
Cholesterol in LDL [Mass/volume] in Serum or Plasma by Direct assay	100.8	0 - 130	mg/dL
Cholesterol in HDL [Mass/volume] in Serum or Plasma	32.2 L	50 - 100	mg/dL

Device Use

Device	Date (since)
Home nebulizer (physical object)	31-May-1999
Blood glucose meter (physical object)	02-Jul-1960